ClinicalTrials.gg
Status unknownNCT02453893Updated May 27, 2015

Risperidone-controlled,Multicentre Clinical Trial of Iloperidone in Patients With Schizophrenia

A Phase 3 interventional study of Iloperidone and Risperidone in Schizophrenia, sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-05-27.

Sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2015), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
288
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing iloperidone in Schizophrenia — 2 open to participants now, 2 under way, 1 of them phase 3. iloperidone · Schizophrenia.

Planned enrollment
5th of 11
288 · median 260
Started
2013
the only one that year
Phase 3
4 of 11
1 open now
Registered
7th of 11
by date
Lead sponsor
1 of 11
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Among the 11 studies testing iloperidone in Schizophrenia, this one is the 5th largest by planned enrollment, is the only one that started in 2013, is one of 4 in phase 3, and was the 7th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

2 of the 11 studies testing iloperidone in Schizophrenia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About iloperidone

iloperidone: first FDA approval 2009 (FANAPT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing iloperidone in Schizophrenia, or all of them as a file.
02

Study summary

This research is a Randomized, double-blind, risperidone-controlled, multicenter clinical study. Chinese subjects with Ischemic Schizophrenia.

Read the detailed description

Subjects will randomly enter into one of two groups,the period of treatment is 8 weeks.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Iloperidone
  • Risperidone
  • PANSS
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • men and women aged 18 to 65 years with schizophrenia;
  • PANSS total score of at least 70 at screening and baseline;
  • at least 2 more than 4 points in 7 of PANSS-P;
  • .

Exclusion criteria

Exclusion Criteria:

  • allergy with iloperidone or risperidone;
  • psychotic symptoms failing to improve after sufficient exposure to 2 antipsychotic treatment;
  • any other primary Axis 1 psychiatric diagnosis;
  • a history of alcohol or drug dependence in recent 1 year;
  • at imminent risk of harm to self or others;
  • systolic blood pressure≤90mmHg。
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
288 participants (estimated)

Study arms

  • Experimental
    oral iloperidone

    2\~12mg/day for 2 weeks,12\~24mg/day for 6 weeks.

    Drug: Iloperidone

  • Active comparator
    oral risperidone

    1\~3mg/day for 2 weeks,3\~6mg/day for 6 weeks.

    Drug: Risperidone

Interventions

06

What researchers measure

Primary outcomes

  1. the score of Positive and Negative syndrome scale to evaluation the severity of schizophrenia

    Time frame: 8 weeks

Secondary outcomes

  1. the score of clinical global impressions to evaluation the severity of illness

    Time frame: 8 weeks

  2. the score of clinical global impressions to evaluation the improvement of illness

    Time frame: 8 weeks

07

Study locations

1 of 1 sites recruiting
  • Shanghai Mental Health Center
    Shanghai, Shanghai 200030, China
    Recruiting
    • Li Hua fang, Ph.D · Contact86-021-34773128
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2013 and a primary completion of Jun 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2015
First posted
May 27, 2015
Start
Nov 2013
Primary completionEst.
Jun 2015
Last update
May 27, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02453893
Responsible party
Sponsor
First posted
May 27, 2015
Start date
Nov 2013
Primary completion
Jun 2015 (estimated)
Last update
May 27, 2015

Study contacts

Wang yu mei, master
Contact
86-311-67808816
Li hua fang, Ph.D
study director · Shanghai Mental Health Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iloperidone

Start the discussion